TAKEDA PHARMACEUTICAL CO LTD current report, Q1 FY2024

Vollständiges Dokument

Takeda Pharmaceutical Co Ltd - Form 6-K Summary

Business Context and Reporting Period

This filing covers the nine-month period ended December 31, 2023 (April 1 to December 31, 2023). Takeda Pharmaceutical Company Limited is a global pharmaceutical company listed on the Tokyo Stock Exchange (TSE Code: 4502). The financial statements are prepared in accordance with International Financial Reporting Standards (IFRS).

Key Financial Metrics

Metric 9 Months Ended Dec 31, 2023 9 Months Ended Dec 31, 2022 Change (AER)
Revenue JPY 3,212.9 billion JPY 3,071.3 billion +4.6%
Operating Profit JPY 224.1 billion JPY 401.9 billion -44.2%
Profit Before Tax JPY 100.3 billion JPY 327.2 billion -69.3%
Net Profit JPY 147.2 billion JPY 285.9 billion -48.5%
Core Operating Profit JPY 865.6 billion JPY 954.7 billion -9.3%
Basic EPS JPY 94.10 JPY 184.32 -48.9%
Total Assets JPY 14,222.9 billion JPY 13,957.8 billion +1.9%
Total Equity JPY 6,742.6 billion JPY 6,354.7 billion +6.1%
Cash & Equivalents JPY 288.4 billion JPY 685.1 billion -57.9%
Operating Cash Flow JPY 437.8 billion JPY 683.5 billion -36.0%

Material Changes vs. Prior Period

  • Revenue Growth: Revenue increased 4.6% on an Actual Exchange Rate (AER) basis, driven by favorable foreign exchange rates and growth in Plasma-Derived Therapies (PDT), Immunology, Gastroenterology (GI), and Rare Diseases. This offset declines in Oncology and Neuroscience due to generic erosion and competition.
  • Profit Decline: Operating profit fell 44.2% primarily due to a JPY 119.3 billion increase in impairment losses (including JPY 74.0 billion for ALOFISEL and JPY 28.5 billion for EXKIVITY) and higher R&D expenses. Net finance expenses also rose significantly.
  • Product Performance:
    • GI: ENTYVIO sales grew 13.0% AER; DEXILANT declined 34.5% due to loss of exclusivity.
    • Rare Diseases: TAKHZYRO grew 16.7% AER; FEIBA declined 11.3% due to competition.
    • PDT Immunology: Immunoglobulin products grew 24.4% AER driven by strong global demand.
    • Neuroscience: VYVANSE/ELVANSE declined 6.7% AER due to generic entry in the U.S., partially offset by growth in ADDERALL XR and INTUNIV.
  • Balance Sheet: Cash and cash equivalents decreased by JPY 245.2 billion, largely due to increased commercial paper drawings and payments for acquisitions (TAK-279 and HUTCHMED license). Total bonds and loans increased to JPY 4,664.2 billion.

Guidance, Outlook, and Risks

  • Full Year Forecast (FY2023): Takeda has not revised its full-year forecast announced on October 26, 2023.
    • Revenue: JPY 3,980 billion (-1.2% vs prior year).
    • Operating Profit: JPY 225 billion (-54.1% vs prior year).
    • Net Profit: JPY 93 billion (-70.7% vs prior year).
    • Core Operating Profit: JPY 1,015 billion (-14.6% vs prior year).
  • Management Guidance (CER Basis):
    • Core Revenue: Low-single-digit % decline.
    • Core Operating Profit: Low-10s % decline.
    • Core EPS: Low-20s % decline.
  • Key Risks and Contingencies:
    • AbbVie Litigation: Takeda recorded an additional JPY 25.3 billion loss in other operating expenses and JPY 6.6 billion in finance expenses related to the supply agreement litigation. A judgment of USD 506 million is payable in April 2024.
    • Tax Settlement: Takeda settled a tax assessment with Irish Revenue Commissioners for EUR 130 million, resulting in a JPY 63.5 billion reduction in tax expenses for the period.
    • Impairments: Significant impairment charges were recognized for ALOFISEL and EXKIVITY.

Investor Verification Checklist

  • Verify the impact of the USD 506 million AbbVie litigation payment scheduled for April 2024 on future liquidity.
  • Monitor the sustainability of revenue growth in GI and Rare Diseases segments amidst generic competition in Neuroscience and Oncology.
  • Assess the trajectory of R&D expenses and potential future impairment charges given the current pipeline investments.
  • Review the cash flow statement to understand the utilization of cash for acquisitions (TAK-279, HUTCHMED) and debt management.
  • Confirm the assumptions behind the "Low-20s % decline" in Core EPS guidance for the full fiscal year.